Table 3. Ongoing Randomized Phase III Trials of Neoadjuvant Immunotherapy With or Without Chemotherapy in NSCLC.

	Eligible patients	Intervention	Estimated enrolment	The primary endpoint
ChekMate 816 NCT02998528	IB-IIIA	Arm A: Platinum doublet × 3 cycles → Surgery → CT ± RT Arm B: Nivolumab + Platinum doublet × 3 cycles → Surgery → CT ± RT	n=350	DFS pCR
IMpower030 NCT03456063	II, IIIA, select IIIB	Arm A: Atezolizumab + Platinum doublet × 4 cycles → Surgery → Atezolizumab Arm B: Placebo + Platinum doublet × 4 cycles → Surgery → Placebo	n=302	MPR DFS
KEYNOTE 671 NCT03425643	IIB-IIIA	Arm A: Pembrolizumab + Platinum doublet × 4 cycles → Surgery → Pembrolizumab. Arm B: Placebo + Platinum doublet × 4 cycles → Surgery → Placebo	n=786	DFS OS
ChecMate 77T NCT04025879	II-IIIB	Arm A: CT + Nivolumab → Surgery + Nivolumab Arm B: CT + Placebo → Surgery + Placebo	n=452	DFS
AEGEAN NCT03800134	IIIA-IIIB	Arm: CT + Durvalumab → Surgery Arm B: CT + Placebo → Surgery	n=300	MPR

CT: Chemotherapy, RT: Radiotherapy, DFS: Disease-free survival, pCR: Pathological complete response, MPR: Major pathological response, OS: Overall survival